Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1

The androgen receptor (AR) is a central driver of aggressive prostate cancer. After initial treatment with androgen receptor signaling inhibitors (ARSi), reactivation of AR signaling leads to resistance. Alternative splicing of AR mRNA yields the AR-V7 splice variant, which is currently an undruggab...

Descripción completa

Detalles Bibliográficos
Autores principales: Melnyk, James E., Steri, Veronica, Nguyen, Hao G., Hwang, Y. Christina, Gordan, John D., Hann, Byron, Feng, Felix Y., Shokat, Kevan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913362/
https://www.ncbi.nlm.nih.gov/pubmed/35087237
http://dx.doi.org/10.1038/s41388-022-02179-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913362/
https://www.ncbi.nlm.nih.gov/pubmed/35087237
http://dx.doi.org/10.1038/s41388-022-02179-z

Ejemplares similares